News

The debate over the most effective methods for genetic testing is an important one.

Despite some key pieces of federal legislation passed in recent years, most drugs-about 93%-are still not studied in neonates. Of those drugs that researchers have studied in this vulnerable population and that bear labels reflecting the changes in pediatric prescribing information, only about half (54%) are used in the neonatal intensive care unit (NICU).

Ongoing studies may lead FDA to stiffen its bioequivalence rules for generic antiepileptic drugs (AEDs) and others with so-called narrow therapeutic indices, according to research presented at American Epilepsy Society (AES) annual meeting recently in Washington, D.C., according to MedPage Today.

Last week, the New England Compounding Center's owners and insurers agreed to establish a $100 million compensation fund for its creditors, including the victims who were injured after receiving injections of contaminated steroids produced by the now bankrupt NECC. Victims have until Wednesday, January 15 to submit their claims in the case.

Changes will impact Medicare, Medicaid, tax policy and the competitive landscape.

URAC recognizes best practices

Oregon is the first state to transfer Medicaid populations into accountable care.

Social media and personal calls patch rough relations.

Focus on exchanges gives plans an opening to repair their image among consumers.

Tools help patients and physicians

Reinvent your market approach for long-term survival

Differentiate your brand as B2B becomes B2C

Discussion leaves a sense of uncertainty as to how coverage rules will play out

Invest in efficiency and consider big data

There are 20 states choosing not to expand their Medicaid programs under the ACA.

Federal and state exchanges scrambled in December to remedy the workarounds

Four criteria

New cost pressures cloud the financial outlook

Will ACA exchanges earn 90% satisfaction ratings someday?

Florida Blue creates single-specialty ACOs

Few feel prepared for March deadline

Long-term intervention encompasses entire lifetime

Capitalize on industry changes in 2014

FDA has rejected alemtuzumab (Lemtrada, Genzyme, a Sanofi company) for the treatment of relapsing forms of multiple sclerosis.

NEJM researchers find the reasons behind the slowdown

Consumers have another 24 hours to shop and sign up

The newly enrolled individuals to the healthcare exchanges will be faced with higher out-of-pocket costs for their medications than those who receive insurance through their employers, according to an analysis by Avalere Health of more than 600 health plans in the exchanges.

Insurers face yet another about-face to accommodate consumers